Guggenheim Capital LLC decreased its stake in Pfizer Inc. (NYSE:PFE) by 6.3% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,752,100 shares of the biopharmaceutical company’s stock after selling 185,261 shares during the period. Pfizer comprises 0.3% of Guggenheim Capital LLC’s investment portfolio, making the stock its 27th largest position. Guggenheim Capital LLC’s holdings in Pfizer were worth $96,901,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Ronna Sue Cohen raised its position in shares of Pfizer by 0.4% in the second quarter. Ronna Sue Cohen now owns 7,881 shares of the biopharmaceutical company’s stock worth $277,000 after buying an additional 35 shares during the last quarter. Delphi Private Advisors LLC raised its position in shares of Pfizer by 1.2% in the second quarter. Delphi Private Advisors LLC now owns 4,007 shares of the biopharmaceutical company’s stock worth $141,000 after buying an additional 47 shares during the last quarter. Acadia Trust NA raised its position in shares of Pfizer by 0.5% in the second quarter. Acadia Trust NA now owns 14,032 shares of the biopharmaceutical company’s stock worth $494,000 after buying an additional 67 shares during the last quarter. New England Private Wealth Advisors LLC raised its position in shares of Pfizer by 0.4% in the second quarter. New England Private Wealth Advisors LLC now owns 18,135 shares of the biopharmaceutical company’s stock worth $639,000 after buying an additional 77 shares during the last quarter. Finally, Darrell & King LLC raised its position in shares of Pfizer by 0.5% in the second quarter. Darrell & King LLC now owns 17,550 shares of the biopharmaceutical company’s stock worth $567,000 after buying an additional 81 shares during the last quarter. Hedge funds and other institutional investors own 69.68% of the company’s stock.

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Pfizer Inc. (NYSE:PFE) traded down 2.69% during mid-day trading on Friday, reaching $32.59. 35,803,589 shares of the company were exchanged. The stock’s 50-day moving average is $32.56 and its 200-day moving average is $34.24. Pfizer Inc. has a 12 month low of $28.25 and a 12 month high of $37.39. The company has a market cap of $197.68 billion, a P/E ratio of 32.72 and a beta of 0.90.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, November 1st. The biopharmaceutical company reported $0.61 earnings per share for the quarter, missing the Zacks’ consensus estimate of $0.62 by $0.01. Pfizer had a net margin of 13.09% and a return on equity of 23.66%. The company earned $13.05 billion during the quarter, compared to analyst estimates of $13.05 billion. During the same quarter last year, the business earned $0.60 EPS. The company’s revenue for the quarter was up 7.9% compared to the same quarter last year. Equities analysts expect that Pfizer Inc. will post $2.41 earnings per share for the current year.

The business also recently declared a quarterly dividend, which will be paid on Thursday, December 1st. Investors of record on Friday, November 11th will be given a $0.30 dividend. The ex-dividend date is Tuesday, November 8th. This represents a $1.20 dividend on an annualized basis and a dividend yield of 3.68%. Pfizer’s dividend payout ratio (DPR) is 106.20%.

Several analysts have recently commented on PFE shares. Piper Jaffray Cos. set a $54.00 price objective on shares of Pfizer and gave the company a “buy” rating in a report on Tuesday, August 23rd. Jefferies Group lowered their price target on shares of Pfizer from $40.00 to $39.00 and set a “buy” rating on the stock in a report on Tuesday, September 13th. Bank of America Corp. set a $40.00 price objective on shares of Pfizer and gave the stock a “buy” rating in a research report on Monday, August 22nd. Credit Suisse Group AG restated an “outperform” rating and set a $40.00 price objective on shares of Pfizer in a research report on Monday, August 22nd. Finally, Vetr cut shares of Pfizer from a “strong-buy” rating to a “buy” rating and set a $36.36 price objective for the company. in a research report on Thursday, October 13th. Thirteen analysts have rated the stock with a hold rating, eleven have assigned a buy rating and two have issued a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average target price of $37.74.

In related news, insider Anthony J. Maddaluna sold 10,000 shares of the stock in a transaction on Wednesday, November 9th. The stock was sold at an average price of $33.00, for a total value of $330,000.00. Following the completion of the transaction, the insider now owns 112,087 shares in the company, valued at approximately $3,698,871. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Albert Bourla sold 18,390 shares of the firm’s stock in a transaction dated Friday, November 4th. The stock was sold at an average price of $30.05, for a total value of $552,619.50. Following the sale, the insider now owns 149,199 shares of the company’s stock, valued at $4,483,429.95. The disclosure for this sale can be found here. 0.07% of the stock is owned by corporate insiders.

About Pfizer

Pfizer Inc is a research-based global biopharmaceutical company. The Company is engaged in discovering, developing and manufacturing of healthcare products. Its portfolio includes medicines, vaccines and medical devices, as well as consumer healthcare products. Its products include Prevnar/Prevenar 13, Lyrica, Enbrel, Lipitor, Viagra, Sutent, BeneFIX, Genotropin, ReFacto, Xyntha and Enbrel.

5 Day Chart for NYSE:PFE

Receive News & Stock Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related stocks with our FREE daily email newsletter.